Evaluating safety and efficacy
Our clinical trials and initiative
Phase I
A Phase I Study with the intent to assess the safety of psilocybin when administered to healthy participants.
Phase II
A Phase II Study with the intent to assess the efficacy of psilocybin when administered to frontline healthcare workers with COVID-19-related mental health concerns.
Palliative Care Trials
End-of-life anxiety in palliative care patients is extremely prevalent, and conventional methods are not sufficient in treating such anxiety. Psilocybin-assisted therapy not only holds the promise of high levels of efficacy, but also allows for patients to discover personal insights in a shorter period of time than conventional methods, which is crucial for palliative care patients whose time is limited.
It is important for this population of patients to have access to this medicine, and the evaluation of safety and efficacy of psilocybin in this population will move it closer to legalization. This is a study that we plan to undertake in the near future.

Meet Tony White
Terminal cancer patient Tony White is the first Albertan to have undergone legal psychedelic therapy in Canada since Health Canada started allowing palliative care patients to take magic mushrooms to relieve end-of-life distress last year.